TABLE 1.
Noncancer Drugs Associated With Improved Cancer Survival From the VUMC and Mayo Clinic EHRs
| VUMC | Mayo Clinic | |||
|---|---|---|---|---|
| Drug Name | HR (95% CI) | FDR-Adjusted P | HR (95% CI) | FDR-Adjusted P |
| Detected from both VUMC and Mayo Clinic EHRs* | ||||
| Rosuvastatin | 0.81 (0.69 to 0.95) | .0691 | 0.68 (0.50 to 0.92) | .0846 |
| Simvastatin | 0.84 (0.79 to 0.90) | < .001 | 0.82 (0.76 to 0.87) | < .001 |
| Amlodipine | 0.84 (0.79 to 0.90) | < .001 | 0.85 (0.78 to 0.93) | .0054 |
| Tamsulosin | 0.87 (0.80 to 0.96) | .0435 | 0.71 (0.59 to 0.85) | .0061 |
| Metformin | 0.88 (0.80 to 0.97) | .0571 | 0.87 (0.80 to 0.95) | .0173 |
| Omeprazole | 0.89 (0.84 to 0.94) | .0006 | 0.90 (0.85 to 0.96) | .0120 |
| Warfarin | 0.90 (0.85 to 0.96) | .0084 | 0.90 (0.84 to 0.96) | .0174 |
| Lisinopril | 0.91 (0.86 to 0.97) | .0328 | 0.93 (0.89 to 0.97) | .0173 |
| Metoprolol | 0.92 (0.86 to 0.98) | .0519 | 0.69 (0.61 to 0.77) | < .001 |
| Detected from the VUMC EHR | ||||
| Olmesartan | 0.72 (0.59 to 0.89) | .0200 | 0.90 (0.56 to 1.4) | .8827 |
| Sildenafil | 0.73 (0.65 to 0.82) | < .001 | 1.0 (0.74 to 1.4) | .9683 |
| Phenobarbital | 0.77 (0.63 to 0.94) | .0603 | 0.83 (0.60 to 1.2) | .5775 |
| Carvedilol | 0.78 (0.68 to 0.90) | .0090 | 0.96 (0.83 to 1.1) | .8763 |
| Diclofenac | 0.81 (0.69 to 0.96) | .0945 | 0.73 (0.55 to 0.98) | .1794 |
| Carbamazepine | 0.84 (0.73 to 0.97) | .0981 | 1.0 (0.82 to 1.3) | .9415 |
| Ramipril | 0.85 (0.76 to 0.95) | .0451 | 0.99 (0.81 to 1.2) | .9785 |
| Epoetin | 0.85 (0.79 to 0.93) | .0023 | 1.7 (0.98 to 2.8) | .2429 |
| Olanzapine | 0.85 (0.75 to 0.97) | .0981 | 1.1 (0.83 to 1.6) | .7084 |
| Atorvastatin | 0.86 (0.80 to 0.93) | .0018 | 0.92 (0.83 to 1.0) | .3921 |
| Esomeprazole | 0.89 (0.84 to 0.95) | .0040 | 0.88 (0.69 to 1.1) | .5669 |
| Celecoxib | 0.91 (0.84 to 0.98) | .0944 | 0.68 (0.48 to 0.96) | .1441 |
| Lansoprazole | 0.92 (0.86 to 0.98) | .0771 | 0.91 (0.80 to 1.0) | .4002 |
| Detected from the Mayo Clinic EHR | ||||
| Midazolam | 1.0 (0.94 to 1.0) | .9964 | 0.43 (0.27 to 0.67) | .0053 |
| Pravastatin | 0.87 (0.76 to 1.0) | .2091 | 0.64 (0.54 to 0.75) | < .001 |
| Venlafaxine | 0.95 (0.84 to 1.1) | .6654 | 0.69 (0.54 to 0.87) | .0190 |
| Oxybutynin | 1.0 (0.70 to 0.91) | .8439 | 0.79 (0.68 to 0.91) | .0174 |
| Lovastatin | 0.92 (0.81 to 1.0) | .4504 | 0.81 (0.72 to 0.92) | .0173 |
| Captopril | 0.99 (0.86 to 1.1) | .9057 | 0.85 (0.75 to 0.96) | .0488 |
| Hydrochlorothiazide | 0.99 (0.93 to 1.1) | .8307 | 0.92 (0.87 to 0.96) | .0054 |
NOTE. Study covariates were patient demographics (age, biologic sex, race), tumor information (type, stage), diseases, and medications. Abbreviations: EHR, electronic health record; FDR, false discovery rate; HR, hazard ratio; VUMC, Vanderbilt University Medical Center.